Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Registry of Patients With Isolated Severe Tricuspid Regurgitation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01502462
Recruitment Status : Completed
First Posted : December 30, 2011
Last Update Posted : February 2, 2021
Sponsor:
Information provided by (Responsible Party):
Jong-Min Song, Asan Medical Center

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Prospective registry for patients with severe isolated tricuspid regurgitation (TR) without significant left-sided valvular or myocardial diseases.

Aim: To evaluate clinical course and prognostic factors of patients with severe isolated TR.


Condition or disease
Tricuspid Regurgitation

Detailed Description:

Inclusion criteria Severe isolated TR for more than 6 months

Exclusion criteria

  1. Severe mitral and aortic valvular heart disease
  2. Age equals to or more than 75 years
  3. Malignancy or serious comorbidity with life expectancy < 5years
  4. Acute or subacute infective endocarditis requiring antibiotics therapy
  5. Untreated hyperthyroidism
  6. Constrictive pericarditis
  7. Unclosed significant atrial septal defect
  8. Previous tricuspid valve surgery
  9. Significant coronary artery disease
  10. Cardiomyopathy
  11. Pregnancy
  12. Severe resting pulmonary hypertension(TR Vmax >4.0 m/s)
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 131 participants
Observational Model: Cohort
Time Perspective: Prospective
Actual Study Start Date : February 2012
Actual Primary Completion Date : December 30, 2020
Actual Study Completion Date : December 30, 2020
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. all cause death [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Hospitalization of cardiovascular causes [ Time Frame: 5 years ]
  2. tricuspid valve surgery [ Time Frame: 5 years ]
  3. stroke [ Time Frame: 5 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Prospective registry for patients with severe isolated tricuspid regurgitation (TR) without significant left-sided valvular or myocardial diseases.

Aim: To evaluate clinical course and prognostic factors of patients with severe isolated TR

Criteria

Inclusion criteria

  • Severe isolated TR for more than 6 months

Exclusion criteria

  1. Severe mitral and aortic valvular heart disease
  2. Age equals to or more than 75 years
  3. Malignancy or serious comorbidity with life expectancy < 5years
  4. Acute or subacute infective endocarditis requiring antibiotics therapy
  5. Untreated hyperthyroidism
  6. Constrictive pericarditis
  7. Unclosed significant atrial septal defect
  8. Previous tricuspid valve surgery
  9. Significant coronary artery disease
  10. Cardiomyopathy
  11. Pregnancy
  12. Severe resting pulmonary hypertension(TR Vmax >4.0 m/s)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01502462


Locations
Layout table for location information
Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
Asan Medical Center
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Jong-Min Song, Associate professor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT01502462    
Other Study ID Numbers: Severe_Isol_TR
First Posted: December 30, 2011    Key Record Dates
Last Update Posted: February 2, 2021
Last Verified: February 2021
Keywords provided by Jong-Min Song, Asan Medical Center:
Clinical course and prognostic factors in patients with severe isolated TR
Additional relevant MeSH terms:
Layout table for MeSH terms
Tricuspid Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases